Last Updated on January 4, 2024 by The Health Master
New Delhi: The U.S. health regulator said that it is working to address a shortage of a particular form of albuterol, a medication used to treat breathing conditions, as its sole manufacturer Akorn has stopped production.
The U. S. Food and Drug Administration (USFDA) added that it is working closely with manufacturers in the supply chain to “understand, mitigate and prevent or reduce any related impacts” due to the shortage of the medication.
“All other strengths and vial sizes are currently available to meet market demand at hospitals and beyond,” the USFDA said on Twitter.
The shortage only impacts a very specific dosage form of the medication generally used in hospitals and that it does not impact albuterol inhalers for personal use, according to the regulator.
IPC joins dialogue between EP, JP & USP for Pharmacopoeial harmonisation
Health Minister directs FDA officers to promote generic drugs
Drug recall: 4,000 bottles of Tacrolimus Capsules recalled due to this reason
Bulk Drug capital of world: Andhra Pradesh has the potential
Understanding DQ, IQ, PQ, and OQ in the Pharma Industry
Jan Aushadhi counters to be mandatory at Medical Stores: Goa
MDTL: State governments to establish Medical Devices Testing Laboratories
FDA issues show cause notices to 17 Pharma manufacturers: Maharashtra
Spurious drugs worth Rs 7.3 cr seized in UP: Odisha connection
Duties and responsibilities of QA person in Pharma Industry
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
